We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Elite Pharmaceuticals, | AMEX:ELI | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
September 29, 2008
---------------------------
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
|
001-15697 |
22-3542636
|
||
------------
|
------------- |
--------------
|
||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation)
|
File Number) | Identification No.) |
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On September 29, 2008 the Registrant issued a press release announcing the acceptance by the U.S. Food and Drug Administration (the FDA) of the Abbreviated New Drug Application for a generic equivalent of a synthetic narcotic analgesic drug product that was filed with the FDA in collaboration with ThePharmaNetwork, LLC.
A copy of the Press Release, dated September 29, 2008, is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
a) |
Not applicable. |
|
b) |
Not applicable. |
|
c) |
Not applicable. |
|
d) |
Exhibits |
|
Exhibit No. | Exhibit | ||
99.1 | Press Release, dated September 29, 2008 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 1, 2008
ELITE PHARMACEUTICALS, INC. | ||
By: | /s/ Bernard Berk | |
Name: | Bernard Berk | |
Title: | Chief Executive Officer |
2
1 Year Elite Pharmaceuticals Chart |
1 Month Elite Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions